Galderma Research & Development

Galderma Holding Sa

Galderma S.a.

Centre National De La Recherche Scientifique

Galderma Research & Development Snc

Jean-Guy Boiteau

Laurence Clary

Corinne Millois Barbuis

Jerôme Aubert

Thibaut Gerfaud

Branislav Musicki

Craig Steven Harris

Loïc Tomas

Michel Rivier

Sandrine Talano

Patricia Rossio

Marlène Schuppli-Nollet

Jean-Claude Pascal

Johan Olsson

Hotan Mojarradi

Karine Bouquet

Etienne Thoreau

Pascale Mauvais

Jean-Michel Linget

Laura Jing Jing

Rachel Auzely-Velty

Tamiris Figueiredo

Laurent Chantalat

André Jomard

Sandrine Chambon

Nicolas Rodeville

Sebastien Daver

Katarina Edsman

Jérôme Aubert

Jacques Eustache

Pierre Van De Weghe

Vincent Rodeschini

Lars Nord

Elin Säwén

Veronique Parnet

Anne-Pascale Luzy

C&eacute;line Tarnus

Gérard Feraille

Véronique Parnet

Loic Tomas

Helena LÄRKNER

A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.

Method of crosslinking glycosaminoglycans

The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.

Carbohydrate crosslinker

A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more cyclodextrin molecules, and further comprising a guest molecule capable of forming a guest-host complex with the aminocyclodextrin molecule acting as a host, wherein the guest molecule is a retinoid, preferably adapalene, or a RAM BA. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent.

Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof

A hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent. A process of preparing a hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules.

Grafting of cyclodextrin by amide bonds to an ether cross-linked hyaluronic acid and uses thereof

The present invention relates to a novel process for preparing enantiomerically pure compounds of N-(pyrid-4-yl)-2-hydroxyalkylamide type corresponding to the general formula (C) below:  and also to processes for preparing the reaction intermediates used in this synthesis, said intermediates having the general formulae (A) and (B) below: 

Method for synthesizing enantiomerically pure N-(pyridin-4-yl)-2-hydroxy-alkylamide derivatives

A process for manufacturing a cross-linked hyaluronic acid (HA) containing a functionalizing group including the step of reacting HA with a mixture of: (i) a first cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, and (ii) a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a second cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, to obtain a cross-linked HA containing the functionalizing group. The process provides a cross-linked hyaluronic acid (HA) containing a functionalizing group. The process utilizes a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a cross-linking agent.

Single step functionalization and cross-linking of hyaluronic acid

Enantiomers of butanediol diglycidyl ether (BDDE) are present in an enantiomerically enriched enantioenriched mixture of BDDE stereisomers or in an enantiomerically pure BDDE. Enantiomerically enriched or pure BDDE is useful as a cross-linking agent, such as in the preparation of a cross-linked hyaluronic acid product.

Enantiopure or enantioenriched BDDE and its use as crosslinking agent in the manufacture of cross-linked products

A method is described for the synthesis of 4-(heterocycloalkyl)-benzene-1,3-diol compounds of general formulae (I) and (II): wherein X can be an oxygen atom or a sulphur atom. Also described, is a method for the synthesis of the reactive intermediates of general formula (7a) or (7b) Novel compounds as synthesis intermediates are also described.

Method for the synthesis of 4-(heterocycloalkyl)-benzene-1,3,-diol compounds

A method is described for the synthesis of 4-piperidin-4-yl-benzene-1,3-diol of the following formula (I): and the pharmaceutically acceptable salts thereof. Also described, is tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate as a novel intermediate compound 

Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate

Methods for preparing disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds that correspond to general formula (I) are described. Also described are pharmaceutical compositions that include the compounds, and methods of using the compounds and compositions for the treatment of chemokine-mediated diseases.

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds represented by the general formula (I) are described. Also described, are pharmaceutical compositions including these compounds and the use of these compounds and compositions for the treatment of chemokine-mediated pathologies.

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.

Growing community of inventors

Valbonne, France

Jean-Guy Boiteau